Establishment of a Research and Development Center for Bioinformatics and Genetic Analysis
First written in FY2018-Q1. 2 of 3 entries say "Restated". Latest entry: FY2018.
1 other company's latest entry also says "Restated".
- FY2018RestatedAnnual report
「To strengthen R&D in information analysis technologies centered on bioinformatics, we opened a new R&D center, SkyFront Research Campus, at the Life Innovation Center in King SkyFront, the Tonomachi International Strategic Base in Kawasaki Ward, Kawasaki. 」
The opening of SkyFront Research Campus and the strengthening of R&D in information analysis technologies centered on bioinformatics have been reiterated. - FY2018-Q3RestatedAnnual report
「To strengthen R&D in information analysis technologies centered on bioinformatics, we opened a new R&D center, SkyFront Research Campus, at the Life Innovation Center in King SkyFront, the Tonomachi International Strategic Base in Kawasaki, Kanagawa. The area is home to a concentration of leading life sciences companies and research institutions, and by establishing an R&D center there, we will promote collaboration with research institutions, universities and companies in the Kanto region.」
The opening of SkyFront Research Campus and the strengthening of R&D in information analysis technologies through collaboration with research institutions, universities and companies have been reiterated. - FY2018-Q1First statedAnnual report
「To strengthen R&D in information analysis technologies centered on bioinformatics, we opened a new R&D center, SkyFront Research Campus, at the Life Innovation Center in King SkyFront, the Tonomachi International Strategic Base in Kawasaki, Kanagawa. The area is home to a concentration of leading life sciences companies and research institutions, and by establishing an R&D center there, we will promote collaboration with research institutions, universities and companies in the Kanto region. Our subsidiary 理研ジェネシス also opened the RIKEN GENESIS Innovation Genome Center in the same facility. By introducing state-of-the-art genetic analysis equipment, including next-generation sequencers and liquid biopsy systems, and providing genetic analysis services and clinical sequencing tests to international quality standards, we will contribute to the advancement of genomic medicine.」
New R&D centers for bioinformatics and genetic analysis by 理研ジェネシス were established. The Company stated for the first time that it would promote genomic medicine through collaboration with research institutions, universities and companies, and through genetic analysis services and clinical sequencing tests using next-generation sequencers and other technologies.